Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2025-03-31 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Please find attached the File
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding a change in the status of a subsidiary company due to allotment of shares to related parties, resulting in a reduction of the parent company's ownership from 100% to 80%. It references compliance with SEBI Listing Regulations and provides detailed disclosure under Regulation 30. The content is an announcement of a corporate event affecting shareholding structure, specifically a change in subsidiary status, rather than a financial report or detailed management discussion. There are no financial statements or earnings data presented. The document is regulatory in nature, disclosing a material event to the stock exchanges as required by law. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure under listing obligations.
2025-03-31 English
Agreements
Capital/Financing Update Classification · 95% confidence The document is an intimation to stock exchanges under Regulation 30 of the SEBI Listing Regulations, dated March 29, 2025. It announces the approval of a term loan facility of Rs. 25 crore from Shinhan Bank by the Finance Committee of the Board of Directors. The document includes detailed disclosures about the loan agreement, parties involved, terms, and guarantees, as required by SEBI circulars. There are no financial statements or comprehensive financial analysis present, nor is this a full report like an annual or interim report. The document is a regulatory announcement about a financing event, specifically a loan agreement approval and related disclosures. This fits the category of Capital/Financing Update (CAP). The document length is 6909 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the classification is CAP with high confidence.
2025-03-29 English
Execution of Loan Agreement
Capital/Financing Update Classification · 95% confidence The document is an intimation to stock exchanges under Regulation 30 of the SEBI Listing Regulations, dated March 29, 2025. It announces the approval of a term loan facility of Rs. 25 crore from Shinhan Bank by the Finance Committee of the Board of Directors. The document includes detailed disclosures about the loan agreement, parties involved, terms, and guarantees, as required by SEBI regulations. There is no financial statement or comprehensive financial analysis present, nor is this a full report or earnings release. The document is a regulatory announcement about a financing event, specifically a loan agreement approval and related disclosures. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 6909 characters, sufficient to provide substantive details about the financing but not a full financial report.
2025-03-29 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal notice from Morepen Laboratories Limited addressed to stock exchanges regarding the closure of the trading window. It references SEBI regulations related to insider trading and states that the trading window will be closed from April 1, 2025, until 48 hours after the announcement of audited financial results for the quarter and financial year ended March 31, 2025. The document does not contain any financial data, results, or detailed report content but is an announcement related to trading restrictions ahead of financial results disclosure. The document length is short (1957 characters) and serves as a regulatory compliance notice rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document.
2025-03-27 English
Closure of Trading Window
Regulatory Filings Classification · 95% confidence The document is a notice titled 'Intimation of Closure of Trading Window' issued by Morepen Laboratories Limited. It references SEBI (Prohibition of Insider Trading) Regulations and informs about the closure of the trading window from April 1, 2025, until 48 hours after the announcement of audited financial results for the quarter and financial year ended March 31, 2025. The document does not contain any financial data, results, or detailed report content. It is a regulatory announcement related to insider trading compliance and timing of trading restrictions around financial results disclosure. The document length is short (1957 characters), and it serves as an announcement rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-03-27 English
General Updates
Regulatory Filings Classification · 100% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the incorporation of a step-down subsidiary company, Quick Med Private Limited. It references compliance with SEBI Listing Regulations and SEBI circulars, indicating it is a regulatory disclosure. The content details the subsidiary's incorporation, shareholding structure, business purpose, and other related information. There are no financial statements, earnings data, or management discussion of financial results. The document is an announcement of a corporate event (incorporation of a subsidiary) rather than a financial report or detailed management report. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-03-20 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.